Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren
- 1 October 2004
- journal article
- leitthema
- Published by Springer Nature in Der Onkologe
- Vol. 10 (10) , 1098-1110
- https://doi.org/10.1007/s00761-004-0771-7
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Radiolabelled peptides for tumour therapy: current status and future directionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumoursAnnals of Oncology, 2002
- Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignanciesSeminars in Nuclear Medicine, 2002
- Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology groupSeminars in Nuclear Medicine, 2002
- Letter to the editorEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidneyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- End-stage renal disease after treatment with 90 Y-DOTATOCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapyInternational Journal of Cancer, 2001
- Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapyInternational Journal of Cancer, 1998